[DOI] [PMC free article] [PubMed] [Google Scholar] 623.Ceriello A., De Nigris V., Pujadas G., La Sala L., Bonfigli A.R., Testa R
For the first time, a pharmacological obesity treatment, semaglutide, has been shown to reduce major adverse cardiovascular events in people with obesity and established cardiovascular disease and there are ongoing cardiovascular outcome trials with other incretin therapies
That "market-share traction clearly demonstrates that physicians and patients prefer Zepbound" over Wegovy, Bernstein analyst Courtney Breen wrote in a separate note on Thursday
This is the peak difficulty period
In an embryofetal development study in pregnant rabbits, subcutaneous doses of 0.0010, 0.0025 or 0.0075 mg/kg/day (0.06-, 0.6- and 4.4-fold the MRHD) were administered throughout organogenesis from Gestation Day 6 to 19
Because semaglutide slows gastric emptying, your provider might suggest adjusting when you take your other prescriptions to ensure they remain effective